Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 8c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.44 +3.42%
Financial Fact:
Total operating expenses: 39.14M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Financial Fact:
Total operating expenses: 39.14M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of ($0.03), $0.08 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $41.3 million versus the consensus estimate of $43.92 million.
Sees Q4 combined net product sales from both HETLIOZ and Fanapt $42 to $48 million
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- Prenetics Global (PRE) Tops Q2 EPS by 18c
- uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
